Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Wang

Pediatric Hematology-Oncology Aurora, CO Medical Doctor

NPI 1588749238 CMS profile 949606

13123 E 16Th Ave, Aurora, CO 80045

Open in the dashboard

General payments

$224,570

180 records reported · program years 2019–2025

Research payments

$37,253

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,605,797 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Wang of Aurora, CO is reported in the CMS Open Payments database as having received $224,570 across 180 general payments and $37,253 in research payments paid to them. Separately, studies naming them as principal investigator received $2,605,797 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $1,250 1
2024 General $36,658 17
2024 Research $10,013 7
2023 General $24,143 32
2023 Research $4,262 4
2022 General $45,944 48
2022 Research $5,775 3
2021 General $10,680 9
2021 Research $780 1
2020 General $32,994 12
2020 Research $4,995 2
2019 General $74,151 62
2019 Research $10,177 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Wang
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Michael Wang were reported at $0. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Michael Wang Pediatric Hematology-Oncology median Middle half National median
2019 $74,151 $184 $69–$2,094 $163
2020 $32,994 $220 $37–$3,941 $114
2021 $10,680 $366 $63–$4,909 $132
2022 $45,944 $181 $66–$2,775 $149
2023 $24,143 $175 $62–$2,600 $160
2024 $36,658 $227 $66–$2,992 $164
2025 $0 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $60,372 38 payments
  2. BioMarin Pharmaceutical Inc. $36,442 22 payments
  3. Novo Nordisk Inc $27,329 17 payments
  4. Bioverativ Therapeutics Inc. $23,747 23 payments
  5. Genzyme Corporation $22,116 14 payments
  6. HEMA Biologics, LLC $21,299 34 payments
  7. Genentech USA, Inc. $17,031 19 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $9,675 4 payments
  9. F. Hoffmann-La Roche AG $6,047 3 payments
  10. Pfizer Inc. $330 1 payment
  11. Other $181 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $132,618 31 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,984 22 payments
  3. Travel and Lodging $30,585 57 payments
  4. Honoraria $16,027 4 payments
  5. Food and Beverage $5,355 66 payments
Products named General payments · program years 2019–2025
  1. Idelvion $35,303 19 payments
  2. HEMLIBRA $23,078 22 payments
  3. Afstyla $21,755 11 payments
  4. SevenFact $21,218 33 payments
  5. FITUSIRAN $17,495 16 payments
  6. HEMGENIX $5,955 2 payments
  7. RiaSTAP $5,878 1 payment
  8. Esperoct $4,050 1 payment
  9. CEPROTIN $3,375 1 payment
  10. Albuminar-25 $2,135 1 payment
  11. Other $4,098 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $13,196 8 payments
  2. Shire North American Group Inc $9,019 8 payments
  3. Pfizer Inc. $5,090 4 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $4,995 2 payments
  5. Bioverativ Therapeutics Inc. $2,953 5 payments
  6. Genzyme Corporation $2,000 3 payments

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record